Impact of Race on Clinical Outcomes After Implantation With a Fully Magnetically Levitated Left Ventricular Assist Device: An Analysis From the MOMENTUM 3 Trial.


Journal

Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941

Informations de publication

Date de publication:
10 2021
Historique:
pubmed: 17 9 2021
medline: 22 12 2021
entrez: 16 9 2021
Statut: ppublish

Résumé

Heart failure disproportionately affects Black patients. Whether differences among race influence outcomes in advanced heart failure with use of a fully magnetically levitated continuous-flow left ventricular assist device remains uncertain. We included 515 IDE (Investigational Device Exemption) clinical trial patients and 500 Continued Access Protocol patients implanted with the HeartMate 3 left ventricular assist device in the MOMENTUM 3 study (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3). Outcomes were compared between Black and White left ventricular assist device recipients for the primary end point of survival free of disabling stroke or reoperation to replace or remove a malfunctioning device at 2 years, overall survival, adverse events, 6-minute walk distance, and quality of life scores. Of 1015 HeartMate 3 patients, 675 were self-identified as White and 285 as Black individuals. The Black patient cohort was younger, more obese and with a history of hypertension, and more nonischemic cause of heart failure, relative to the White patient group. Black and White patients did not experience a difference in the primary end point (81.1% versus 77.9%; hazard ratio, 1.08 [95% CI, 0.76-1.54], Although the survival free of disabling stroke or reoperation to replace/remove a malfunctioning device at 2 years with the HM 3 left ventricular assist device did not differ by race, Black HeartMate 3 patients experienced a higher morbidity burden and smaller gains in functional capacity and quality of life when compared with White patients. These findings require efforts designed to better understand and overcome these gaps through systematic identification and tackling of putative factors. Registration: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02224755 and NCT02892955.

Sections du résumé

BACKGROUND
Heart failure disproportionately affects Black patients. Whether differences among race influence outcomes in advanced heart failure with use of a fully magnetically levitated continuous-flow left ventricular assist device remains uncertain.
METHODS
We included 515 IDE (Investigational Device Exemption) clinical trial patients and 500 Continued Access Protocol patients implanted with the HeartMate 3 left ventricular assist device in the MOMENTUM 3 study (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3). Outcomes were compared between Black and White left ventricular assist device recipients for the primary end point of survival free of disabling stroke or reoperation to replace or remove a malfunctioning device at 2 years, overall survival, adverse events, 6-minute walk distance, and quality of life scores.
RESULTS
Of 1015 HeartMate 3 patients, 675 were self-identified as White and 285 as Black individuals. The Black patient cohort was younger, more obese and with a history of hypertension, and more nonischemic cause of heart failure, relative to the White patient group. Black and White patients did not experience a difference in the primary end point (81.1% versus 77.9%; hazard ratio, 1.08 [95% CI, 0.76-1.54],
CONCLUSIONS
Although the survival free of disabling stroke or reoperation to replace/remove a malfunctioning device at 2 years with the HM 3 left ventricular assist device did not differ by race, Black HeartMate 3 patients experienced a higher morbidity burden and smaller gains in functional capacity and quality of life when compared with White patients. These findings require efforts designed to better understand and overcome these gaps through systematic identification and tackling of putative factors. Registration: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02224755 and NCT02892955.

Identifiants

pubmed: 34525837
doi: 10.1161/CIRCHEARTFAILURE.120.008360
doi:

Banques de données

ClinicalTrials.gov
['NCT02224755', 'NCT02892955']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e008360

Auteurs

Farooq H Sheikh (FH)

Medstar Heart and Vascular Institute, Washington, DC (F.H.S.).

Ashwin K Ravichandran (AK)

Ascension St Vincent, Indianapolis, IN (A.K.R.).

Daniel J Goldstein (DJ)

Montefiore Medical Center, Bronx, NY (D.J.G., S.R.P.).

Richa Agarwal (R)

Duke University Medical Center, Durham, NC (R.A.).

John Ransom (J)

Baptist Health, Heart and Transplant Institute, Little Rock, AR (J.R.).

Aditya Bansal (A)

Ochsner Medical Center, New Orleans, LA (A.B.).

Gene Kim (G)

University of Chicago Medical Center, IL (G.K.).

Joseph C Cleveland (JC)

University of Colorado Hospital, Aurora (J.C.C.).

Nir Uriel (N)

New York Presbyterian and Columbia University (N.U.).

Brett C Sheridan (BC)

California Pacific Medical Center, San Francisco (B.C.S.).

Don Chomsky (D)

St Thomas Hospital, Nashville, TN (D.C.).

Snehal R Patel (SR)

Montefiore Medical Center, Bronx, NY (D.J.G., S.R.P.).

Nick Dirckx (N)

Global Biometrics, Abbott, Plymouth, MN (N.D.).

Abi Franke (A)

Global Clinical Affairs - Heart Failure, Abbott, Sylmar, CA (A.F.).

Mandeep R Mehra (MR)

Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA (M.R.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH